期刊文献+

BRAF^(V600E)突变与乳头状甲状腺癌中央区淋巴结转移的关系 被引量:12

Association of BRAF^(V600E) mutation with central compartment lymph node metastasis in papillary thyroid carcinoma
原文传递
导出
摘要 目的:探讨乳头状甲状腺癌(PTC)中BRAF基因突变的临床意义。方法:选择2年间符合条件的PTC手术患者126例,提取患者石蜡切片中的DNA样本,用荧光PCR法检测BRAF基因V600E(BRAFV600E)的突变情况,分析BRAFV600E突变与PTC患者临床病理因素及中央区淋巴结转移的关系。结果:126例PTC患者BRAFV600E突变的发生率为69.0%(87/126)。单因素与多因素分析显示,BRAFV600E突变与淋巴结转移有关(P<0.05);中央区淋巴结转移与年龄、肿瘤大小、肿瘤分期和BRAFV600E突变有关(均P<0.05)。进一步分析显示,肿瘤直径≤10 mm时,BRAFV600E突变与中央区淋巴结转移无关(P>0.05),肿瘤直径>10 mm时,BRAFV600E突变患者的中央区淋巴结转移率高于突变阴性患者(P<0.05)。结论:BRAFV600E突变是PTC中央区淋巴结转移风险的独立预测因子;对于术前检测BRAFV600E突变阳性患者,肿瘤直径越大越应该重视中央区淋巴结清扫。 Objective:To investigate the clinical significance of the BRAF gene mutation in papillary thyroid carcinoma(PTC).Methods:One-hundred and twenty-two eligible PTC patients undergoing surgical treatment within the past 2years were selected.DNA samples of the patients were extracted from paraffin sections and the V600 E mutation of the BRAF gene(BRAFv600E) was detected by fluorescent PCR.The relations of BRAFv600E mutation with clinicopathologic factors and central compartment lymph node metastasis were analyzed.Results:The incidence of BRAFv600E mutation was 69.0%(87/126) in the 126 PTC patients.Univariate and multivariate analysis showed that BRAFv600E mutation was significantly related to lymph node metastasis(P〈0.05),and central compartment lymph node metastasis was significantly associated with age,tumor size,tumor stage and BRAFv600E mutation(all P〈0.05).Further analysis demonstrated that BRAFv600E mutation had no significant relation with central compartment lymph node metastasis in patients whose tumor size was equal to or less than10 mm(P〉0.05),while among patients with tumor size larger than 10 mm,the incidence of central compartment lymph node metastasis was significantly higher in positive BRAF mutation cases than that in negative BRAFv600E mutation ones(P〈0.05).Conclusion:BRAFv600E mutation is an independent predictor associated with aggressive tumor behavior and is an independent predictive factor for central compartment neck dissection.In those cases with positive BRAFv600Emutation,the larger the size of the tumor,the more important it is to perform central compartment neck dissection.
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2014年第11期1522-1526,共5页 China Journal of General Surgery
基金 黑龙江省自然科学基金资助项目(D201228) 黑龙江省教育厅课题资助项目(12541490) 哈尔滨医科大学附属第二医院青年基金资助项目(QN2012-07)
关键词 甲状腺肿瘤 乳头状 突变 淋巴转移 Thyroid Neoplasms Carcinoma,Papillary Mutation Lymphatic Metastasis
  • 相关文献

参考文献20

  • 1Montero PH, lhrahimpasic T, Nixon IJ, et al. Thyroid metastasectomy[J]. J SurgOncol, 2014, 109(1):36-41.
  • 2石臣磊,石铁锋,吴佳奇,孙宇,秦华东.桥本甲状腺炎对乳头状甲状腺癌颈淋巴结转移的影响[J].中国普通外科杂志,2013,22(5):580-584. 被引量:22
  • 3吴恢升,何劲松,陈伟财,王先明.选择性颈淋巴结清除术在乳头状甲状腺癌手术治疗的临床应用[J].中国普通外科杂志,2012,21(5):532-535. 被引量:17
  • 4Moo TA, McGill J, Allendorf J, et al. Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma[J]. World J Surg, 2010, 34(6): 1187-1191.
  • 5Kim KH, Kang DW, Kim SH, et al. Mutations of the BRAE gene in papillary thyroid carcinoma in a Korean population[J]. Yonsei Med J, 2004, 45(5):818-821.
  • 6Chakraborty A, Narkar A, Mukhopadhyaya R, et al. BRAE V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion[J]. EndocrPathol, 2012, 23(2):83-93.
  • 7Stratmann M, Sekulla C, Dralle H, et al. Current TNM system of the UICC/AJCC : the prognostic significance for differentiated thyroid carcinoma[J]. Chirurg, 2012, 83(7):646-651.
  • 8Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer[J]. Nature, 2002, 417(6892):949-954.
  • 9Tadmor T, Tiacci E, Falini B, et al.Thc BRAF-V600E mutation in hematological malignancies: a new player in hairy cell leukemia and Langerhans cell histioeytosis[j].Leuk Lymphoma, 2012, 53(12):2339- 2340.
  • 10Garnett M J, Marais R. Guilty as charged: B-RAF is a human oncogene[J]. Cancer Cell, 2004, 6(4):313-319.

二级参考文献85

  • 1应敏刚,陈建顺,肖景榕,陈增春,周衍.长乐市1988~2002年恶性肿瘤发病率时间趋势分析[J].中国肿瘤,2005,14(1):32-34. 被引量:21
  • 2钱碧云,陈可欣,何敏,董淑芬,韩宏伟,雷蕾,王继芳.天津市区甲状腺癌流行状况调查[J].中国肿瘤临床,2005,32(4):218-221. 被引量:56
  • 3李树玲.我国甲状腺癌外科现状与展望[J].临床外科杂志,2006,14(3):129-130. 被引量:46
  • 4陈士超,何春年.用于甲状腺肿瘤鉴别诊断的相关分子标记物[J].临床与实验病理学杂志,2007,23(3):350-353. 被引量:11
  • 5Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Vase report on 53856 cases of thyroid carcinoma treated in the U.S. A 1985 - 1995 [J]. Cancer, 1998, 83(12) :2638 -2648.
  • 6Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973 -2002 [J]. JAMA, 2006, 295(18) :2164 -2167.
  • 7Hegediis L. Clinical practice. The thyroid nodule [ J ]. N Engl J Med, 2004,351(17) :1764- 1771.
  • 8Shuntaro I, Mikiharu F, Yoshto U, et al. B-raf, a new member of the raf family is activated by DNA rearrangement [J]. Mol Cell Biol, 1988, 8(6) :2651 -2654.
  • 9Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer [ J]. Nature, 2002, 417 (6892) :949 -954.
  • 10Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target [ J ]. Bioehimieaet Biophysiea Acta, 2003, 1653(1) :25 -40.

共引文献67

同被引文献137

引证文献12

二级引证文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部